The Zhitong Finance App learned that Jin Xin Reproduction (01951) rose more than 5%. As of press release, it had risen 5.24% to HK$4.22, with a turnover of HK$21.51 million.

According to the news, on June 15, the Beijing Municipal Health Insurance Administration issued a notice. Starting July 1, 16 therapeutic assisted reproductive technology projects will be included in the city's basic medical insurance reimbursement, and newborns in the city can enjoy medical insurance benefits after birth. In response, Huacheng Securities released a research report stating that since the inclusion of assisted reproduction in medical insurance is expected to accelerate the increase in industry penetration in the future, with strong operational integration capabilities and excellent brands and platforms, Jin Xin's fertility market share (number of egg retrieval cycles) is expected to increase steadily. The bank maintains its “Recommended” rating with a target price of HK$7.10.